Aclaris Therapeutics completes patient enrollment in Phase 2 trial of bosakitug

Aclaris Therapeutics (ACRS) announced that it has completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of bosakitug, or ATI-045, in patients with moderate-to-severe atopic dermatitis, or AD. Top line results are expected in the fourth quarter of 2026. This randomized, double-blind, placebo-controlled Phase 2 trial will evaluate the efficacy and safety of bosakitug in 109 patients with moderate-to-severe atopic dermatitis. The primary efficacy endpoint is percent change from baseline in Eczema Area and Severity Index, or EASI, at week 24. Secondary endpoints at week 24 include EASI response validated Investigator Global Assessment, or IGA, response, body surface area response, and Peak Pruritus Numerical Rating Scale score, relative to baseline. Safety, tolerability, pharmacodynamic (PD) biomarkers, and pharmacokinetic profile will also be assessed.